Drug Safety Labeling Changes
The summary view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. The “quick view” table below provides the drug name and sections modified. Click on the drug name to go to the detailed view. The detailed view includes sections and subsections modified, a description of new or modified safety information in the BOXED WARNING, CONTRAINDICATIONS, or WARNINGS sections, and a link to the revised prescribing information.
Key to Label Section Acronyms:
BW=BOXED WARNING, C=CONTRAINDICATIONS, W=WARNINGS, P=PRECAUTIONSAR=ADVERSE REACTIONS, PPI/MG=PATIENT PACKAGE INSERT/MEDICATION GUIDE
BW
C
W
P
AR
Avinza (morphine sulfate) Extended-Release Capsules
*ER/LA opioid analgesics
Butrans (buprenorphine) Transdermal System
Dolophine (methadone hydrochloride) Tablets
Duragesic (fentanyl transdermal system)
Embeda (morphine sulfate and naltrexone hydrochloride) Extended-Release Capsules
Exalgo (hydromorphone HCl) Extended-Release Tablets
Kadian (morphine sulfate) Extended-Release Capsules
MS Contin (morphine sulfate) Extended-Release Tablets
Nucynta ER (tapentadol) extended-release tablets
Opana ER (oxymorphone hydrochloride) Extended-Release Tablets
Oxycontin (oxycodone hydrochloride) Extended-Release Tablets
Palladone (hydromorphone hydrochloride) Extended-Release Capsules
Prezista (darunavir) tablets, 75 mg, 150 mg, 600 mg, and 800 mgPrezista (darunavir) oral suspension, 100 mg/mL
Contact us to become a Sponsor